Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Reddit Inc

Tesla

Monday's market action tells us that meme stocks are back in play. However, because not all meme stocks are created equally, investors should focus on those with fundamental catalysts.

Meme Mania is Back: Buy these 3 Stocks

In conjunction with its quarterly report, Novavax announced a pivotal new partnership with Sanofi. Novavax's revenue increased and its losses shrank in Q1.

Novavax's Q1 Results Are Overshadowed by Its Sanofi Partnership

Sanofi

Novavax announced Q1 2024 results with a beat on EPS and a miss on revenue, causing a surge in premarket trading. Novavax finalized a licensing agreement with Sanofi worth up to $1.2B, boosting its COVID-19 vaccine commercial performance. The Sanofi deal revitalizes the outlook for Novavax, providing immediate cash infusion, long-term revenue streams, and a narrowed focus.

Novavax: Sanofi Partnership Revitalizes My Magnum Opus

Novavax, Inc. (NASDAQ:NVAX ) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Executive Officer James Kelly - Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Filip Dubovsky - President of Research and Development Conference Call Participants Roger Song - Jefferies Eric Joseph - JPMorgan Mayank Mamtani - B. Riley Securities Brendan Smith - TD Cowen Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Q1 2024 Earnings Call Transcript

The pharmaceutical company saw measurable but modest growth last quarter, but remains in the red. Its vaccine science, however, has motivated a rival drugmaker to enter into a lucrative partnership.

Why Novavax Stock More Than Doubled Today

Novavax (NASDAQ: NVAX ) stock investors are celebrating on Friday as the vaccine company's shares hit a new 52-week high after announcing a deal with Sanofi (NASDAQ: SNY ). This saw shares of NVAX stock climb as high as $9.22 per share during normal trading hours on Friday.

NVAX Stock Alert: Novavax Just Hit a New 52-Week High

Novavax (NASDAQ: NVAX ) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi (NASDAQ: SNY ) to commercialize its Covid-19 vaccine.

Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal

Novavax, Inc. (NASDAQ:NVAX) shares surged Friday following the announcement of a significant licensing agreement with Sanofi SA (ADR) (NYSE:SNY), valued at $1.2 billion. The deal encompasses the commercialization of a combined COVID-19 and flu shot, marking a pivotal development in the field of vaccine production.

Novavax shares skyrocket after billion-dollar licensing deal with Sanofi

Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi.

Biotech Rockets 125% On Sanofi Covid Vaccine Agreement

Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to license its vaccine technology to French drugmaker Sanofi (SNY).

Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines

Novavax Inc (NASDAQ:NVAX) stock is up 130% to trade at $10.82 today, by far the best stock on the Nasdaq this morning.

Vaccine Stock Explodes After Sanofi Deal

Shares for Novavax swelled by more than 140% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid.

Novavax Shares Surge Over 140% After $1.4 Billion Covid Shot Deal With Sanofi

Novavax (NVAX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $3.41 per share a year ago.

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

Novavax (NASDAQ: NVAX ) stock is on the rise Friday after the biotechnology company announced a deal with Sanofi (NASDAQ: SNY ) alongside its Q1 earnings report. The big news here is the two companies signing a co-exclusive licensing agreement.

Why Is Novavax (NVAX) Stock Up 118% Today?

The two companies will also work on a shot that combines Covid-19 and flu vaccines.

Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.

Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA. Despite reporting a first-quarter loss per share of $1.05, wider than the $0.92 anticipated by analysts, and revenue of $93.

Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses

Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influenza, in a major boost to struggling biotech company.

Novavax shares surge on new $1.4 billion deal with Sanofi

COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice.

Novavax erases doubts about its ability to remain in business

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including : $500 million upfront payment Approximately $70 million equity investment in Novavax Up to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product sales Up to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-M TM  adjuvant Announces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza Combination vaccine trial, which is on-track to initiate second half of 2024, with potential 2026 launch for both candidates Reduced current liabilities by an additional $831 million during Q1 2024 Achieved total revenue in Q1 2024 of $94 million Novavax removes going concern notice Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Sanofi on Friday announced it has reached a 'co-exclusive' licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines.

France's Sanofi in COVID-19 vaccine deal with Novavax - statement

The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.

Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit royalties, for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M™ adjuvant technology Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection GAITHERSBURG, Md. , May 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Plug Power

Petco Health and Wellness

Although Wall Street is captivated by the artificial intelligence (AI) revolution, Nvidia's upside may be limited. Select Wall Street analysts expect far superior returns from three high-risk/high-reward small-cap companies.

Forget Nvidia: These 3 Small-Cap Stocks Offer Up to 557% Upside, According to Select Wall Street Analysts

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Novavax Stock (NVAX)